Gulf Pharmaceutical Industries (JULPHAR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Gulf Pharmaceutical Industries

Why is Gulf Pharmaceutical Industries ?

With a growth in Net Sales of 12.96%, the company declared Very Positive results in Jun 25

The company has declared positive results for the last 4 consecutive quarters
OPERATING CASH FLOW(Y) Highest at AED 145.7 MM
ROCE(HY) Highest at 6.2%
INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost

With ROE of 2.04%, it has a expensive valuation with a 2.00 Price to Book Value

Over the past year, while the stock has generated a return of -20.75%, its profits have risen by 116.3% ; the PEG ratio of the company is 0.8

Underperformed the market in the last 1 year

Even though the market (Abu Dhabi Securities Exchange) has generated returns of 9.12% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -20.75% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Gulf Pharmaceutical Industries should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Gulf Pharmaceutical Industries for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Gulf Pharmaceutical Industries

-100.0%

0.93

48.11%

Abu Dhabi Securities Exchange

-1.29%

1.13

8.08%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

12.32%

EBIT Growth (5y)

18.68%

EBIT to Interest (avg)

0.09

Debt to EBITDA (avg)

58.88

Net Debt to Equity (avg)

0.03

Sales to Capital Employed (avg)

0.89

Tax Ratio

8.83%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

2.69%

ROE (avg)

0.76%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.23

EV to EBIT

15.93

EV to EBITDA

9.32

EV to Capital Employed

1.23

EV to Sales

1.03

PEG Ratio

0.03

Dividend Yield

ROCE (Latest)

7.74%

ROE (Latest)

5.92%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

26What is working for the Company

ROCE(HY)

Highest at 7.08%

DEBT-EQUITY RATIO (HY)

Lowest at -9.04 %

PRE-TAX PROFIT(Q)

At AED 29.6 MM has Grown at 134.92%

NET PROFIT(Q)

Highest at AED 29.5 MM

RAW MATERIAL COST(Y)

Fallen by -14.61% (YoY

NET SALES(Q)

Highest at AED 300.3 MM

OPERATING PROFIT(Q)

Highest at AED 43.6 MM

-3What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at AED 62.4 MM

Here's what is working for Gulf Pharmaceutical Industries

Pre-Tax Profit

At AED 29.6 MM has Grown at 134.92%

over average net sales of the previous four periods of AED 12.6 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (AED MM)

Net Profit

Highest at AED 29.5 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (AED MM)

Net Profit

At AED 29.5 MM has Grown at 168.18%

over average net sales of the previous four periods of AED 11 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (AED MM)

Debt-Equity Ratio

Lowest at -9.04 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales

Highest at AED 300.3 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (AED MM)

Operating Profit

Highest at AED 43.6 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (AED MM)

Raw Material Cost

Fallen by -14.61% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Gulf Pharmaceutical Industries

Operating Cash Flow

Lowest at AED 62.4 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (AED MM)